Dynavax to Report Third Quarter Financial Results and Host Conference Call on November 3, 2022

Rhea-AI Summary

Dynavax Technologies Corporation (Nasdaq: DVAX) is set to report its third quarter financial results on November 3, 2022, post-market close. The company will also host a conference call at 4:30 p.m. ET. Both the call and a following audio webcast will be accessible on Dynavax's investor relations page. Dynavax specializes in developing vaccines, notably its approved products, HEPLISAV-B and the CpG 1018 adjuvant, which is instrumental in various COVID-19 vaccine formulations. More details are available on the company’s website.

Positive

• Scheduled financial results announcement for Q3 may boost investor confidence.
• Potential for increased visibility through the upcoming conference call.

Negative

• None.

EMERYVILLE, Calif., Oct. 20, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report third quarter financial results on Thursday, November 3, 2022, after the U.S. financial markets close.

Dynavax will host a conference call and live audio webcast on Thursday, November 3, 2022, at 4:30 p.m. (ET)/1:30 p.m. (PT).

The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations. A replay of the webcast will be available for 30 days following the live event.

To dial into the call, participants will need to register for the call using the caller registration link. It is recommended that participants dial into the conference call or log into the webcast approximately 10 minutes prior to the call.

About Dynavax
Dynavax is a commercial stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S. and the European Union for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older, and CpG 1018 adjuvant, currently used in multiple adjuvanted COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant as a premier vaccine adjuvant through global research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, plague, shingles, Tdap, seasonal influenza and universal influenza. For more information about our marketed products and development pipeline, visit www.dynavax.com and follow Dynavax on LinkedIn.

Contacts:
Nicole Arndt
Investor Relations and Corporate Communications
narndt@dynavax.com
510-665-7264

Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-report-third-quarter-financial-results-and-host-conference-call-on-november-3-2022-301655383.html

SOURCE Dynavax Technologies

FAQ

What date will Dynavax report its Q3 financial results?

Dynavax will report its Q3 financial results on November 3, 2022.

What time is Dynavax's conference call scheduled for?

The conference call is scheduled for 4:30 p.m. ET on November 3, 2022.

Where can I access the Dynavax conference call?

The conference call can be accessed through the 'Events & Presentations' page on Dynavax's investor relations website.

What products does Dynavax currently have on the market?

Dynavax's marketed products include HEPLISAV-B and the CpG 1018 adjuvant.